<DOC>
	<DOC>NCT01659021</DOC>
	<brief_summary>This study will evaluate the effect of the addition of idelalisib (GS-1101) to ofatumumab on progression-free survival (PFS) in participants with previously treated chronic lymphocytic leukemia (CLL).</brief_summary>
	<brief_title>Efficacy and Safety of Idelalisib (GS-1101; CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<mesh_term>Idelalisib</mesh_term>
	<criteria>Key Adults with previously treated recurrent CLL who have measurable lymphadenopathy Require therapy for CLL Have experienced CLL progression &lt; 24 months since the completion of the last prior therapy Have disease that is not refractory to ofatumumab Note: Other protocol defined Inclusion/Exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>CLL</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>GS-1101</keyword>
	<keyword>CAL-101</keyword>
	<keyword>Ofatumumab</keyword>
</DOC>